Topic Hub
7 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 7 of 7 clinical reviews.
A clinical breakdown of oral micronized progesterone (Prometrium) FAERS safety signals, FDA post-market surveillance findings, label warnings, and what the adverse-event data mean for patients and prescribers.
Read clinical reviewComplete FDA approval history of oral micronized progesterone (Prometrium), including regulatory milestones, label updates, post-market safety data, and clinical trial evidence from PEPI through current guidelines.
Read clinical reviewA comprehensive review of FDA label changes for oral micronized progesterone (Prometrium) from 2020 through 2026, including safety updates, boxed warning revisions, and clinical implications for prescribers.
Read clinical reviewA clinical review of the oral micronized progesterone (Prometrium) regulatory history, current FDA-approved indications, post-market safety data, and next-generation progesterone delivery systems in development.
Read clinical reviewA clinical comparison of how the FDA and EMA regulate oral micronized progesterone (Prometrium/Utrogestan), including labeling differences, boxed warnings, and post-market safety data.
Read clinical reviewA comprehensive review of oral micronized progesterone (Prometrium) regulatory approvals worldwide, FDA labeling, safety data, and clinical evidence supporting its use in hormone therapy.
Read clinical reviewA clinical review of oral micronized progesterone (Prometrium) legal disputes, patent history, generic entry, FDA regulatory milestones, and post-market safety updates.
Read clinical review